NASDAQ:MDWDMediwound Stock Price, Forecast & News

Mediwound's stock was trading at $2.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MDWD shares have increased by 69.1% and is now trading at $3.9073.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mediwound.

Mediwound is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Mediwound.

Mediwound Ltd (NASDAQ:MDWD) released its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.11). Mediwound had a negative return on equity of 85.28% and a negative net margin of 48.34%.
View Mediwound's earnings history.

2 brokers have issued 1-year price objectives for Mediwound's shares. Their forecasts range from $5.50 to $7.00. On average, they expect Mediwound's stock price to reach $6.25 in the next twelve months. This suggests a possible upside of 60.0% from the stock's current price.
View analysts' price targets for Mediwound.

News coverage about MDWD stock has trended very positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mediwound earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Mediwound.

Mediwound saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 48,100 shares, an increase of 14.5% from the July 15th total of 42,000 shares. Based on an average daily volume of 168,900 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the company's shares are short sold.
View Mediwound's Short Interest.

Some companies that are related to Mediwound include Canopy Rivers (RIV), Chromadex (CDXC), Happiness Biotech Group (HAPP), Sundial Growers (SNDL), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), True Drinks (TRUU), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Beleave (BE), Beleave (BE) and Entia Biosciences (ERGO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Blackstone Group (BX), Mastercard (MA), Wells Fargo & Co (WFC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sorrento Therapeutics (SRNE), Alibaba Group (BABA) and Chubb (CB).

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

Mediwound's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Phoenix Holdings Ltd. (0.46%), Thomasville National Bank (0.08%), Harel Insurance Investments & Financial Services Ltd. (0.05%) and Meitav Dash Investments Ltd. (0.04%).

MDWD stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd..

MDWD stock was purchased by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Thomasville National Bank, and Meitav Dash Investments Ltd..

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MDWD stock can currently be purchased for approximately $3.91.

Mediwound has a market capitalization of $106.32 million and generates $31.79 million in revenue each year. The biopharmaceutical company earns $4.95 million in net income (profit) each year or $0.08 on an earnings per share basis. Mediwound employs 73 workers across the globe.

The official website for Mediwound is www.mediwound.com.

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]